The reverse stock split is intended to enable Adicet to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf†gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patie ...

Core Viewpoint - Adicet Bio, Inc. has announced a registered direct offering of 70,001,000 shares of its common stock, along with pre-funded warrants for an additional 10,000,000 shares, indicating a significant capital raise to support its clinical stage biotechnology initiatives [1] Company Summary - Adicet Bio, Inc. is a clinical stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies aimed at treating autoimmune diseases and cancer [1]